Cell Biotech Co. Ltd (049960) - Total Liabilities

Latest as of September 2025: ₩7.46 Billion KRW ≈ $5.06 Million USD

Based on the latest financial reports, Cell Biotech Co. Ltd (049960) has total liabilities worth ₩7.46 Billion KRW (≈ $5.06 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Cell Biotech Co. Ltd generate cash to assess how effectively this company generates cash.

Cell Biotech Co. Ltd - Total Liabilities Trend (2011–2024)

This chart illustrates how Cell Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 049960 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Cell Biotech Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Cell Biotech Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Empress Royalty Corp V:EMPR	Canada	CA$6.09 Million
UOB Kay Hian Securities (Thailand) Public Company Limited BK:UOBKH	Thailand	฿4.16 Billion
Pinar Entegre Et ve Un Sanayi AS IS:PETUN	Turkey	TL5.22 Billion
GlycoNex TWO:4168	Taiwan	NT$542.22 Million
Compass Digital Acquisition Corp NASDAQ:CDAQ	USA	$9.51 Million
AAC Clyde Space AB (publ) ST:AAC	Sweden	Skr224.34 Million
GrandTech C.G. Systems TWO:6123	Taiwan	NT$1.90 Billion
Mobix Labs Inc NASDAQ:MOBX	USA	$28.06 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Cell Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cell Biotech Co. Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	13.72	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cell Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cell Biotech Co. Ltd (2011–2024)

The table below shows the annual total liabilities of Cell Biotech Co. Ltd from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩6.23 Billion ≈ $4.22 Million	+8.23%
2023-12-31	₩5.76 Billion ≈ $3.90 Million	-25.70%
2022-12-31	₩7.75 Billion ≈ $5.25 Million	+25.16%
2021-12-31	₩6.19 Billion ≈ $4.19 Million	+16.42%
2020-12-31	₩5.32 Billion ≈ $3.60 Million	+13.09%
2019-12-31	₩4.70 Billion ≈ $3.19 Million	-26.80%
2018-12-31	₩6.42 Billion ≈ $4.35 Million	+2.26%
2017-12-31	₩6.28 Billion ≈ $4.26 Million	-1.51%
2016-12-31	₩6.38 Billion ≈ $4.32 Million	+2.67%
2015-12-31	₩6.21 Billion ≈ $4.21 Million	+18.44%
2014-12-31	₩5.24 Billion ≈ $3.55 Million	+43.75%
2013-12-31	₩3.65 Billion ≈ $2.47 Million	-6.06%
2012-12-31	₩3.88 Billion ≈ $2.63 Million	-22.03%
2011-12-31	₩4.98 Billion ≈ $3.37 Million	--

About Cell Biotech Co. Ltd

KQ:049960 Korea Biotechnology & Medical Research

Market Cap

$83.71 Million

₩123.52 Billion KRW

Market Cap Rank

#19860 Global

#1129 in Korea

Share Price

₩16000.00

Change (1 day)

-1.42%

52-Week Range

₩11500.00 - ₩16550.00

All Time High

₩56579.38